Letter | Published:

Replacing the complementarity-determining regions in a human antibody with those from a mouse

Nature volume 321, pages 522525 (29 May 1986) | Download Citation

Subjects

Abstract

The variable domains of an antibody consist of a β-sheet framework with hypervariable regions (or complementarity-determining regions—CDRs) which fashion the antigen-binding site. Here we attempted to determine whether the antigen-binding site could be transplanted from one framework to another by grafting the CDRs. We substituted the CDRs from the heavy-chain variable region of mouse antibody B1–8, which binds the hapten NP-cap (4-hydroxy-3-nitrophenacetyl caproic acid; KNP-cap = 1.2 µM), for the corresponding CDRs of a human myeloma protein. We report that in combination with the B1–8 mouse light chain, the new antibody has acquired the hapten affinity of the B1–8 antibody (KNP-cap = 1.9 µM). Such ‘CDR replacement’ may offer a means of constructing human monoclonal antibodies from the corresponding mouse monoclonal antibodies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Proc. natn. Acad. Sci. U.S.A. 70, 3305–3310 (1973).

  2. 2.

    et al. Proc. natn. Acad. Sci. U.S.A. 71, 4298–4302 (1974).

  3. 3.

    , , & J. molec. Biol. 141, 369–391 (1980).

  4. 4.

    , , , & in Sequences of Proteins of Immunological Interest (U.S. Department of Health and Human Services, 1983).

  5. 5.

    & J. molec. Biol. 160, 325–342 (1982).

  6. 6.

    , , & J. molec. Biol. 186, 651–663 (1985).

  7. 7.

    , & Eur. J. Immun. 8, 393–400 (1978).

  8. 8.

    , & J. biol. Chem. 253, 585–597 (1978).

  9. 9.

    , & EMBO J. 1, 629–634 (1982).

  10. 10.

    , & in Immunoglobulin Idiotypes and Their Expression (eds Janeway, C., Wigzell, H. & Fox, C. F.) 169–178 (Academic, New York, 1981).

  11. 11.

    & Proc. natn. Acad. Sci. U.S.A. 78, 1138–1142 (1981).

  12. 12.

    et al. Nature 314, 268–270 (1985).

  13. 13.

    et al. Cell 24, 625–637 (1981).

  14. 14.

    & Proc. natn. Acad. Sci. U.S.A. 78, 2072–2076 (1983).

  15. 15.

    et al. Nature 314, 235–238 (1985).

  16. 16.

    , , & Biochemistry 24, 5858–5861 (1985).

  17. 17.

    , & Trends Biotechnol. 2, 70–77 (1984).

  18. 18.

    , , & J. Immun. 135, 1530–1535 (1985).

  19. 19.

    , , & Proc. natn. Acad. Sci. U.S.A. 81, 6851–6855 (1984).

  20. 20.

    , & Nature 312, 643–646 (1984).

  21. 21.

    , & Eur. J. Immun. 9, 1004–1013 (1979).

  22. 22.

    Meth. med. Res. 10, 115–121 (1964).

  23. 23.

    et al. J. molec. Biol. 170, 1055–1058 (1983).

  24. 24.

    in Enzyme Kinetics, 73–74 (Wiley, New York, 1975).

  25. 25.

    in Computational Crystallography (ed. Sayre, D.) 303–310 (Clarendon, Oxford, 1982).

  26. 26.

    Nucleic Acids Res. 12, 521–538 (1984).

  27. 27.

    & FEBS Lett. 87, 107–110 (1978).

  28. 28.

    , & Gene 33, 103–119 (1985).

  29. 29.

    , & Proc. natn. Acad. Sci. U.S.A. 74, 5463–5467 (1977).

  30. 30.

    & Gene 19, 269–276 (1982).

  31. 31.

    & EMBO J. 1, 655–660 (1982).

  32. 32.

    , & Nature 312, 604–608 (1984).

Download references

Author information

Affiliations

  1. Laboratory of Molecular Biology, Medical Research Council, Hills Road, Cambridge CB2 2QH, UK

    • Peter T. Jones
    • , Paul H. Dear
    • , Jefferson Foote
    • , Michael S. Neuberger
    •  & Greg Winter

Authors

  1. Search for Peter T. Jones in:

  2. Search for Paul H. Dear in:

  3. Search for Jefferson Foote in:

  4. Search for Michael S. Neuberger in:

  5. Search for Greg Winter in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/321522a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.